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cognition, neurodegeneration, neuroprotection, aging. 
 
ABSTRACT 
As populations increase their life expectancy, age-related neurodegenerative disorders 
such as Alzheimer’s disease have become more common. I2-Imidazoline receptors (I2-
IR) are widely distributed in the central nervous system, and dysregulation of I2-IR in 
patients with neurodegenerative diseases has been reported, suggesting their implication 
in cognitive impairment. This evidence indicates that high-affinity selective I2-IR ligands 
potentially contribute to the delay of neurodegeneration. In vivo studies in the female 
senescence accelerated mouse-prone 8 mice have shown that treatment with I2-IR ligands, 
MCR5 and MCR9, produce beneficial effects in behavior and cognition. Changes in 
molecular pathways implicated in oxidative stress, inflammation, synaptic plasticity, and 
apoptotic cell death were also studied. Furthermore, treatments with these I2-IR ligands 
diminished the amyloid precursor protein processing pathway and increased Aβ 
degrading enzymes in the hippocampus of SAMP8 mice. These results collectively 
demonstrate the neuroprotective role of these new I2-IR ligands in a mouse model of brain 
aging through specific pathways and suggest their potential as therapeutic agents in brain 
disorders and age-related neurodegenerative diseases.  
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INTRODUCTION 
Imidazoline receptors (non-adrenergic receptors for imidazolines) [1] have been 
identified as a promising biological target that deserves further investigation using 
multidisciplinary approaches to build a comprehensive understanding of their 
pharmacological possibilities. To date, three main imidazoline receptors, I1-, I2- and I3-
IR, have been identified as binding sites that recognize different radiolabeled ligands 
involving different locations and physiological functions [2-4]. The pharmacological 
characterization of I1-IR is understood the best, and they are used in the antihypertensive 
drugs moxonidine [5] or rilmenidine [6]. To date, I2-IR have not been structurally 
described, although García-Sevilla’s group has defined distinct binding proteins 
corresponding to subgroups of I2-IR sites [7]. I2-IR are involved in analgesia [8] glial 
tumors [9], inflammation [10] and a plethora of brain disorders, such as AD [11,12], 
Parkinson’s disease (PD) [13], and different psychiatric disorders [14-16]. The efficacy 
of the analgesic CR4056 in osteoarthritis has advanced this compound in the first-in-class 
I2-IR ligand to achieve phase II clinical trials [17]. I2-IR are widely distributed in the 
CNS, binds imidazoline-based compounds [18, 19], such as idazoxan or valldemossine 
[20], and have been associated with the catalytic site of monoamine oxidase enzyme 
(MAO) [21]. A neuroprotective role for I2-IR was described through the pharmacological 
activities observed for their ligands [22]. Idazoxan reduced neuron damage in the 
hippocampus after global ischemia in the rat brain [23] and agmatine, identified as the 
endogenous I2-IR ligand [24], has demonstrated modulatory actions in several 
neurotransmitters that produce neuroprotection both in vitro and in rodent models [25]. 
The compelling evidence has demonstrated that other selective I2-IR ligands (Figure 1) 
provide benefits such as being neuroprotective against cerebral ischemia in vivo [26, 27], 
inducing beneficial effects in several models of chronic opioid therapy, leading to 
neuroprotection by direct blocking of N-methyl-D-aspartate receptor (NMDA) mediated 
intracellular [Ca2+] influx [28], or provoking morphological/biochemical changes in 
astroglia that are neuroprotective after neonatal axotomy [22].  
At a cellular level, I2-IR are situated in the outer membrane of the mitochondria in 
astrocytes [29], and a direct physiological function of glial I2-imidazoline preferring sites 
that regulate the level of the astrocyte marker glial fibrillary acidic protein (Gfap) has 
been proposed [30]. In addition, astrogliosis is a pathophysiological trend in brain 
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neurodegeneration as in AD [31]. The density of I2-IR is markedly increased in the brains 
of patients with AD [13], and in gliosis associated wiht brain injury [32]. 
The pharmacological characterization of these receptors relies on the discovery of 
selective I2-IR ligands devoid of a high affinity for I1-IR and α2-adrenoceptors. The 
reported I2-IR ligands are structurally restricted, featuring rigid substituted pattern 
imidazolines, and most of which are not entirely selective and thus interact with α-
adrenoceptors [19], which causes side effects [33]. Our chemistry program aimed to find 
new selective I2-IR ligands to increase the arsenal of pharmacological tools to exploit the 
therapeutic potential of I2-IR in neuroprotection.  
We have recently synthesized a series of new chemical scaffolds, 2-imidazolin-4-
yl)phosphonates [34], by an isocyanide-based multicomponent reaction under microwave 
irradiation to avoid using solvents. The experimental synthetic conditions fulfill the 
principles of green chemistry, giving access to novel compounds with high selectivity and 
affinity for I2-IR. Among them, we tested MCR5 [diethyl (1-(3-chloro-4-fluorobenzyl)-
5,5-dimethyl-4-phenyl-4,5-dihydro-1H-imidazol-4-yl)phosphonate] in previous work to 
demonstrate its neuroprotective and analgesic effects, and it showed promising results in 
models of brain damage [35]. In particular, mechanisms of neuroprotection related to 
regulating apoptotic pathways or inhibiting p35 cleavage mediated by this new active 
compound have been found. In the present work, we explored the behavioral and 
cognitive status, including molecular changes associated with age and neurodegenerative 
processes, presented by SAMP8 mice when treated with the new highly selective I2-IR 
ligands MCR5 and MCR9 [methyl 1-(3-chloro-4-fluorobenzyl)-5,5-dimethyl-4-phenyl-
4,5-dihydro-1H-imidazole-4-carboxylate] (Figure 2). SAMP8 is a naturally occurring 
mouse strain that displays a phenotype of accelerated aging with cognitive decline, as 
observed in AD, and is widely used as a feasible rodent model of cognitive dysfunction 
[36]. To the best of our knowledge, this manuscript reports the first study that includes 
cognitive and behavioral parameters of novel I2-IR ligands in a well-characterized animal 
model for studying brain aging and neurodegeneration.  
 
 
Material and methods 
Synthesis of I2-IR ligands MCR5 and MCR9  
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The compounds were prepared using our previously optimized conditions [34]. I2-IR pKi 
for MCR5 and MCR9 were determined as 9.42±0.16 nM and 8.85±0.21 nM, 
respectively, showing that both compounds also had high selectivity against α2 adrenergic 
receptors (457 and 1862, respectively) [35].  
The blood-brain barrier (BBB) determination method 
The in vitro permeability (Pe) of the novel compounds through a lipid extract of the 
porcine brain was determined using a mixture of PBS/EtOH 70:30. The concentration of 
drugs was determined using a UV/VIS (250-500 nm) plate reader. Assay validation was 
carried out by comparing the experimental and reported permeability values of 14 
commercial drugs (see supporting information), which provided a good linear correlation: 
Pe (exp) = 1.003 Pe (lit) _ 0.783 (R2 = 0.93). Using this equation and the limits established 
by Di et al. [37] for BBB permeation, the following ranges of permeability were 
established: Pe (10-6 cm·s-1) > 5.18 for compounds with high BBB permeation (CNS+); 
Pe (10-6 cm·s-1) < 2.06 for compounds with low BBB permeation (CNS_); and 5.18 > Pe 
(10-6 cm·s-1) > 2.06 for compounds with uncertain BBB permeation (CNS±). 
Measurements of hypothermic effects  
For this study, 25 adult male CD-1 mice (30-40 g) bred in the animal facility at the 
University of the Balearic Islands were used. Mice were housed in standard cages under 
defined environmental conditions (22°C, 70% humidity, and a 12-h light/dark cycle, 
lights on at 8:00 AM) and with free access to a standard diet and tap water. Experimental 
procedures followed the ARRIVE [38] and standard ethical guidelines (European 
Communities Council Directive 86/609/EEC and Guidelines for the Care and Use of 
Mammals in Neuroscience and Behavioral Research, National Research Council 2003) 
and were approved by the Local Bioethics Committee (UIB-CAIB). All efforts were made 
to minimize the number of mice used and their suffering. 
Mice were handled and weighed by the same person for 2 days so they could habituate to 
the experimenter before any experimental procedures were initiated. For the acute 
treatment, mice received a single dose of MCR9 (20 mg/kg, i.p., n=6) or vehicle (a 
mixture of equal parts of DMSO and saline, i.p., n=7). For the repeated treatment, mice 
were daily treated with MCR9 (20 mg/kg, i.p., n=6) or vehicle (a mixture of equal parts 
of DMSO and saline, i.p., n=6) for 5 consecutive days. The hypothermic effect of 
compound MCR9 was evaluated by measuring rectal temperature before any drug 
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treatment (basal value) and 1 h after drug injection by a rectal probe connected to a digital 
thermometer (compact LCD thermometer, SA880-1M, RS, Corby, UK). Mice were 
sacrificed immediately after the last measurement of rectal temperature. 
SAMP8 mouse in vivo experiments 
SAMP8 female mice (n=26) (12 months old) were used to carry out cognitive and 
molecular analyses. We divided these animals randomly into three groups: SAMP8 
Control (SP8-Ct, n=10) and SAMP8 treated with I2-IR ligands (MCR5, n=8 and MCR9, 
n=8). Animals had free access to food and water and were kept under standard 
temperature conditions (22±2°C) and a 12-h light/dark cycle (300 lux/0 lux). MCR5 and 
MCR9 (5 mg/Kg/day) were dissolved in 1,8% 2-hydroxypropyl-β-cyclodextrin and 
administered through drinking water for 4 weeks. Water consumption was controlled each 
week, and I2-IR ligand concentrations were adjusted accordingly to reach the optimal 
dose. 
Studies and procedures involving mice brain dissection and subcellular fractionation were 
performed by the ARRIVE [38] and international guidelines for the care and use of 
laboratory animals (see above) and approved by the Ethics Committee for Animal 
Experimentation at the University of Barcelona. 
Open field (OFT), elevated plus maze (EPM), and novel object recognition test (NORT) 
The OFT apparatus was a white polywood box (50x50x25 cm). The floor was divided 
into two areas defined as center zone and peripheral zone (15 cm between the center zone 
and the wall). Behavior was scored with SMART® ver.3.0 software, and each trial was 
recorded for later analysis using a camera situated above the apparatus. Twenty-six mice 
(n=8-10 per group) were placed at the center and allowed to explore the box for 5 min. 
Afterward, the mice were returned to their home cages and the OFT apparatus was 
cleaned with 70% EtOH. The parameters scored included center staying duration, rears, 
defecations, and the distance traveled, calculated as the sum of total distance traveled in 
5 min.   
The EMP apparatus consists of opened arms and closed arms, crossed in the middle 
perpendicularly to each other, and a central platform (5×5cm) constructed of dark and 
white plywood (30×5×15 cm). To initiate the test session, 26 mice (n=8-10 per group) 
were placed on the central platform, facing an open arm, and allowed to explore the 
apparatus for 5 min. After the 5-min test, mice were returned to their home cages, and the 
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EPM apparatus was cleaned with 70% EtOH and allowed to dry between tests. Behavior 
was scored with SMART® ver.3.0 software, and each trial was recorded for later analysis 
using a camera fixed to the ceiling at a height of 2.1 m and situated above the apparatus. 
The parameters recorded included time spent on opened arms, time spent on closed arms, 
time spent in the center zone, rears, defecation and urination. 
The NORT protocol employed was a modification of that of Ennaceur and Delacour [39]. 
In brief, 26 mice (n=8-10 per group) were placed in a 90°, two-arm, 25-cm-long, 20-cm-
high, 5-cm-wide black maze. The walls could be removed for easy cleaning. Light 
intensity in mid-field was 30 lux. Before performing the test, the mice were individually 
habituated to the apparatus for 10 min for 3 days. On day 4, the animals were submitted 
to a 10-min acquisition trial (first trial), during which they were placed in the maze in the 
presence of two identical, novel objects (A+A or B+B) at the end of each arm. A 10-min 
retention trial (second trial) was carried out 2 h and 24 h later, with one of the two objects 
changed. During these second trials, mice behavior was recorded with a camera. The time 
with the new object (TN) and the time with the old object (TO) were measured. A 
discrimination index (DI) was defined as (TN−TO)/(TN+TO). The maze and the objects 
were cleaned with 96% EtOH after each test to eliminate olfactory cues. 
Brain processing 
Mice were euthanized by cervical dislocation 1 day after the behavioral and cognitive 
tests finished. Brains were immediately removed from the skull. The hippocampus of 
each mouse was then isolated and frozen in powdered dry ice. Each hippocampus was 
maintained at -80°C for further use. Tissue samples were homogenized in lysis buffer 
containing phosphatase and protease inhibitors (Cocktail II, Sigma-Aldrich). Total 
protein levels were obtained and the Bradford method was used to determine protein 
concentration.   
 
Protein levels determination by western blot (WB) 
For WB, aliquots of 15 µg of hippocampal protein were used. Protein samples from 15 
mice (n=5 per group) were separated by SDS-PAGE (8%-12%) and transferred onto 
PVDF membranes (Millipore). Afterward, membranes were blocked in 5% non-fat milk 
in 0,1% Tween20 TBS (TBS-T) for 1 h at room temperature, followed by overnight 
incubation at 4°C with the primary antibodies listed in Table 1 (Supporting Information). 
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Membranes were washed and incubated with secondary antibodies for 1 h at room 
temperature. Immunoreactive proteins were viewed with a chemiluminescence-based 
detection kit, following the manufacturer’s protocol (ECL Kit; Millipore) and digital 
images were acquired using a ChemiDoc XRS+ System (BioRad). Semi-quantitative 
analyses were carried out using ImageLab software (BioRad), and results were expressed 
in arbitrary units, considering control protein levels as 100%. Protein loading was 
routinely monitored by immunodetection of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). 
 
Determination of OS in the hippocampus 
Hydrogen peroxide (H2O2) from 12 mice (n=4 per group) was measured in hippocampal 
tissue protein extracts obtained as described above. It was used as an indicator of OS and 
was quantified using a hydrogen peroxide assay kit (Sigma-Aldrich, St. Louis, MI) 
according to the manufacturer’s instructions. 
RNA extraction and gene expression determination 
Total RNA isolation was carried out using the TRIzol® reagent according to 
manufacturer’s instructions. The yield, purity, and quality of RNA were determined 
spectrophotometrically with a NanoDrop™ ND-1000 (Thermo Scientific) apparatus and 
an Agilent 2100B Bioanalyzer (Agilent Technologies). RNAs with 260/280 ratios and 
RIN higher than 1.9 and 7.5, respectively, were selected. Reverse Transcription-
Polymerase Chain Reaction (RT-PCR) was performed as follows: 2 μg of mRNA was 
reverse-transcribed using the high capacity cDNA reverse transcription kit (Applied 
Biosystems). Real-time quantitative PCR (qPCR) was employed to quantify the mRNA 
expression of OS genes heme oxygenase (decycling) 1 (Hmox1), aldehyde oxidase 1 
(Aox1), cyclooxygenase 2 (Cox2), inflammatory genes interleukin 6 (Il-6), interleukin 1 
beta (Il-1β), tumor necrosis factor alpha (Tnf-α), amyloid processing gene disintegrin, and 
metalloproteinase domain-containing protein 10 (Adam10) and amyloid degradation gene 
neprilysin (NEP). The primers are listed in Table 2 (Supporting Information). 
SYBR® Green real-time PCR was performed in a Step One Plus Detection System 
(Applied-Biosystems) employing SYBR® Green PCR Master Mix (Applied-Biosystems). 
Each reaction mixture contained 7.5 μL of cDNA (a 2-μg concentration), 0.75 μL of each 
primer (a 100-nM concentration, each), and 7.5 μL of SYBR® Green PCR Master Mix 
(2X).  
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TaqMan-based real-time PCR (Applied Biosystems) was also performed in a Step One 
Plus Detection System (Applied-Biosystems). Each 20 μL of TaqMan reaction contained 
9 μL of cDNA (25 ng), 1 μL 20X probe of TaqMan Gene Expression Assays and 10 μL 
of 2X TaqMan Universal PCR Master Mix.  
Data were analyzed using the comparative cycle threshold (Ct) method (ΔΔCt), where 
the housekeeping gene level was used to normalize differences in sample loading and 
preparation. Normalization of expression levels was performed with actin for SYBR® 
green-based real-time PCR results and Tbp for TaqMan-based real-time PCR. Each 
sample (n=4-5 per group) was analyzed in duplicate, and the results represent the n-fold 
difference of the transcript levels among different groups. 
Statistical analysis 
The statistical analyses were conducted using GraphPad Prism ver. 6 statistical software. 
Data were expressed as the mean ± standard error of the mean (SEM). Means were 
compared with one-way analysis of variance (ANOVA) and Tukey’s post hoc test or two-
tailed Student’s t-test when necessary. Statistical significance was considered when p 
values were <0.05. Statistical outliers were performed out with Grubbs' test and were 
removed from the analysis. 
RESULTS  
BBB permeation assay for I2-IR ligands MCR5 and MCR9 
The tested compounds MCR5 and MCR9 had Pe values of 13.5±0.9 and 26.9±1.7, 
respectively, well above the threshold for high BBB permeation, so they were predicted 
to be able to cross the BBB and reach their biological target in the CNS. Supplementary 
information on results analysis can be found in the supporting material (Table 3). 
 
Hypothermic effects of MCR9 in mice 
Selective I2-IR ligands induce hypothermia in rodents [4]. In particular, the hypothermic 
effect of compound MCR5 in mice was evaluated in a recent study from our research 
group (results for compound 2c in ref 35) [35]. Similar to MCR5, MCR9 induced mild 
hypothermia as assessed by a moderate reduction (-2.3°C) in rectal temperature 1 h after 
injection at the tested dose of 20 mg/kg in adult CD-1 mice and as compared with vehicle-
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treated controls (Figure 3A, day 1). While repeated (5 days) administration (20 mg/kg) 
revealed persistent the hypothermic effects of MCR9 from days 1 to 4 (range from -2.3 
to -3.2°C), on day 5 no significant change was observed in body temperature (-1.8°C 
change) as compared with vehicle-treated controls (Figure 3B).  
Beneficial effects on behavior and cognition induced by MCR5 and MCR9 in 
SAMP8 mice 
Results obtained in OFT demonstrated that both compounds increased locomotor activity 
and time spent in the center zone (Figure 4A and B). Furthermore, a significant increment 
in the vertical activity, quantified by the number of total rears, was observed in mice 
treated with MCR5 or MCR9 in OFT and the EPM (Figure 4C and F). EPM data 
indicated a reduction in anxiety-like behavior by a significant decrease in time spent in 
closed arms for treated animals compared with controls (Figure 4E). These results are 
supported by a preference for opened arms, although not significant, for MCR5 (Figure 
4D). Moreover, a significant increase in the DI indicates an improved performance in 
recognition of the new object in the NORT between MCR5- and MCR9-treated SAMP8 
mice compared with the control group. A robust effect in short (2 h) and long-term (24 h) 
memory was found for the two tested compounds (Figure 4G and H).  
OS and inflammatory markers reduced by MCR5 and MCR9 in SAMP8 mice 
OS and neuroinflammation are thought to be key risk factors in the development of 
neurodegeneration. The hydrogen peroxide levels in the hippocampus were significantly 
reduced in brains of mice treated with either MCR5 or MCR9 compared with the control 
group (Figure 5A). Of note, superoxide dismutase 1 (SOD1) protein levels in treated mice 
were reduced by MCR5 but not by MCR9 (Figure 5B). Moreover, Hmox1 gene 
expression, an important key enzyme in cellular antioxidant-defense, was also 
significantly increased with both MCR5 and MCR9 (Figure 5D). Other OS markers, such 
as Aox1 or Cox2, were not significantly altered (Figure 5D). Regarding the inflammation 
markers, no changes were observed in Il-6 gene expression for tested compounds, but a 
significant decrease in Il-1β and Tnf-α for MCR5 treated SAMP8 mice was found (Figure 
5E). Moreover, a significant diminution in Gfap gene expression was determined, 
reinforcing the prevention of inflammatory processes by MCR5 and MCR9 (Figure 5C). 
Changes in synaptic markers and apoptotic factors induced by MCR5 and MCR9 
in SAMP8 mice 
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MCR5, but not MCR9, induced an increase in postsynaptic density protein 95 (PSD95) 
protein levels (Figure 6A). Protein levels for synaptophysin (SYN), a presynaptic protein, 
showed a slight increase for both compounds, although it did not reach significance 
(Figure 6B). To determine the implication of proteolytic processes in the MCR5 and 
MCR9 compounds, we found reduced levels of calpain (data not shown) with a 
significant diminution in 150 α-spectrin breakdown fragment (SPBD) (Figure 6C). 
Furthermore, MCR9 and MCR5 reduced caspase-3 activity in SAMP8 mouse 
hippocampi, because of the diminution of caspase-3 protein levels and 120 SPBD 
fragments, which reached significance for MCR9 (Figure 6C and D). Moreover, B-cell 
lymphoma 2 (Bcl-2) levels were diminished, and Bcl-2-associated X (Bax), a key protein 
in the apoptotic cascade, was reduced by MCR5 (Figure 6E and F), supporting a possible 
implication of I2-IR in apoptosis processes. 
 
Changes in mitogen-activated protein kinase (MAPK) signaling pathways reduced 
hyperphosphorylation of Tau induced by MCR5 and MCR9 in SAMP8 mice 
Key proteins associated with molecular pathways disturbed in brain disorders and 
neurodegeneration were evaluated by WB. Interestingly, MCR5, but not MCR9, 
increased the p-AKT/AKT ratio (protein kinase B) (Figure 7A). Accordingly, higher 
levels of inactivated glycogen synthase kinase 3 beta (GSK3β), phosphorylated in Ser9, 
were determined (Figure 7B). Extracellular signal-regulated kinase (ERK½) inhibition by 
MCR5 and MCR9 was demonstrated by a reduction of the p-ERK½ ratio (Figure 7C). 
Furthermore, cyclin-dependent kinases 5 (CDK5) measured by the p-CDK5/CDK5 and 
p25/p35 ratios were also reduced (Figure 7D and E). Taking into account the results 
obtained on kinases CDK5, GSK3β, AKT, and ERK½, we studied Tau 
hyperphosphorylation levels in the hippocampi of SAMP8 mice. A significant reduction 
in Tau phosphorylation in treated SAMP8 mice was found, specifically for the Ser404 
phosphorylation site, whereas the Ser396 phosphorylation site was reduced without 
reaching significance (Figure 7F).   
Changes in APP processing and Aβ degradation induced by MCR5 and MCR9 in 
SAMP8 mice 
We found a significant increase in sAPPα protein levels in MCR9 treated SAMP8 mice 
(Figure 8A) and a significant reduction in sAPPβ protein levels in MCR5 treated SAMP8 
mice (Figure 8B). Furthermore, a significant increase in gene expression for Adam10, an 
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α-secretase that cleaves APP and NEP, an Aβ degrading enzyme (Figure 8C and D) was 
observed in both treated mice groups compared with that in non-treated animals. 
DISCUSSION 
I2-IR are related to several physiological and pathological processes, including those of 
the CNS, such as pain [8], neuropathic pain [40], seizures [41, 42], and neurodegenerative 
diseases such as AD [14, 43]. Our lab has a research line on developing new high affinity 
and selectivity I2-IR ligands, maintaining the imidazoline scaffold and incorporating 
several substituents in the imidazoline ring. Some of these were previously tested for their 
neuroprotective role [35].  
Given the enormous potential of I2-IR and their implications in brain disorders and 
neurodegenerative diseases such as AD, we set out to explore whether MCR5 and 
MCR9, two members of a structurally new family of I2-IR ligands, might improve the 
behavioral and cognitive status in SAMP8 model mice. The main chemical structural 
differences were a phosphonate substituent on the imidazoline ring for MCR5 in contrast 
with an ester group for MCR9 (Figure 2).  
Published results from our lab demonstrated that MCR5 presented a pKi for the I2-IR of 
9.42±0.16 and high selectivity when compared with the α2 receptor affinity [35]. 
Likewise, MCR9 is a high-affinity I2-IR ligand (pKi 8.85±0.21) but with a higher 
selectivity against α2 receptors. Both MCR5 and MCR9 were predicted to be able to 
cross the BBB, an important drug characteristic when action is expected in the CNS. 
Previous studies have evaluated the effects of selective I2-IR ligands on inducing 
hypothermia in rodents [e.g., idazoxan or BU224] [44]. Accordingly, MCR5 can induce 
hypothermia in mice, and showed a neuroprotective role in kainate-induced seizures, 
modifying levels of a Fas-associated protein with death domain (FADD) receptor [35]. 
While acute MCR5 (5 and 20 mg/kg) induced mild hypothermia, repeated (20 mg/kg, 5 
days) administration of MCR5 revealed significantly attenuated hypothermic effects 
from day 2, which indicated the induction of tolerance to the hypothermic effects of the 
drug [35]. For MCR9, repeated (20 mg/kg, 5 days) administration revealed persistent 
hypothermic effects up to day 4. These results suggest that the slow induction of tolerance 
to the hypothermic effects caused by MCR9 might be started following 5 days of drug 
administration, although a more extended treatment paradigm might be needed for 
confirmation. 
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The hypothermic effects exerted by MCR5 and MCR9 might be relevant to induce 
neuroprotection because it was previously proposed for some of the neuroprotective 
effects induced by the I2-IR selective ligand idazoxan. Several experiments have 
ascertained a possible role for hypothermia in mediating neuroprotection. For example, 
small drops in temperature exerted neuroprotection in cerebral ischemia [45] and are 
typically used in the clinic to improve the neurological outcome under various 
pathological conditions (e.g., stroke, brain injury). Although the mechanisms explaining 
the neuroprotective effects mediated by hypothermia are not well understood, some 
researchers have suggested that they might be related to the inhibition of glutamate release 
[46]. 
SAMP8 mice have been studied as a non-transgenic murine mouse model of accelerated 
senescence and late-onset AD. These mice exhibit cognitive and emotional disturbances, 
probably due to the early development of pathological brain hallmarks, such as OS, 
inflammation, and activation of neuronal death pathways, which mainly affect the 
cerebral cortex and hippocampus [47, 48]. To date, this rodent model has not been used 
to test I2-IR ligands. Thus, this work is the first investigation of the effects of the 
improvement of cognitive impairment and behavior in this mouse model after treatment 
with I2-IR ligands.  
Behavioral and cognitive effects were investigated through three well-established tests in 
SAMP8 mice: the OFT, which is an experiment used to assay general locomotor activity 
and anxiety in rodents [49]; the EPM, one of the most widely used tests for measuring 
anxiety-like behavior [50]; and the NORT, as a standard measure of cognition (for short- 
and long-term memory) [51].   
The OFT and EPM parameters indicated a reduction in cognitive impairment through 
showing improved locomotor activity jointly with an anti-anxiousness effect. Likewise, 
the NORT results demonstrated an improvement in cognitive and short- and long-term 
learning capabilities in hippocampal memory processes. Therefore, all the assessed 
parameters showed robust beneficial effects on cognition and behavior after MCR5 and 
MCR9 treatment in SAMP8 mice. 
The results in cognitive and behavioral effects were supported by a cellular and 
biochemical assessment of characteristic parameters related to cognitive decline and AD. 
The compelling evidence demonstrated a neuroprotective role for I2-IR. The 
neuroprotective role can be related to OS and inflammation [52] by measuring OS 
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indicators and inflammation markers in SAMP8 mouse brain tissue treated with the I2-IR 
ligands, MCR5 and MCR9. Results showed significant reduced hydrogen peroxide 
levels in hippocampal tissue and increased Hmox1 gene expression in treated MCR5 and 
MCR9 SAMP8 mice, but not in other sensors for OS, such as Aox1 or Cox2. SOD1 
protein levels were reduced by MCR5 but not by MCR9. Regarding inflammation 
markers, no changes were observed in Il-6 gene expression for tested compounds, but a 
significant decrease in Il-1β and Tnf-α for MCR5 treated SAMP8 mice was found. In 
addition, reduced astrogliosis was found in treated animals, corroborating a reduced 
inflammatory environment in hippocampi of MCR5 and MCR9 treated SAMP8 mice. 
Altogether these results showed a relatively weak influence in OS and inflammation 
mechanisms by I2-IR ligands in SAMP8 mice [53-57]. However, a role for those two 
pathological conditions related to I2-IR ligand interaction cannot be discarded because 
MCR5 elicited beneficial effects despite the old age of the SAMP8 mice. Aged SAMP8 
mice present lower inflammation and OS due to being at the endpoint of the senescence 
process [56, 57]. Therefore, it can be challenging to determine drug effects on these 
processes in aged SAMP8 mice.  
MCR5 and MCR9 effects on key molecular markers for synapsis and apoptosis were 
studied to unravel the prevention of cognitive decline by I2-IR ligands in SAMP8 mice, 
which is characterized by alterations in those processes. In consonance with better 
cognitive performance, the compounds tested increased synaptic markers such as SYN 
and PSD95, indicating a neuroprotective role for MCR5 and MCR9.  
There are several cellular and molecular pathways related to better synaptic performance, 
including proteolytic and phosphorylation activities or apoptotic processes. Regarding 
proteolytic processes, calpain is an intracellular protease that cleaves the CDK5 activator 
p35 to a p25 fragment. MCR5 and MCR9 diminished calpain levels and its activity with 
a reduced 150 SPBD fragment. Moreover, a significant reduction in p25 protein levels 
was found in treated SAMP8 mice. A decrease in p25 can also influence CDK5 activity, 
as implicated in Tau phosphorylation [58, 59]. These results indicate that CDK5 
phosphorylation activity should be diminished after I2-IR ligand treatment, corroborating 
results obtained previously for MCR5 in a kainate model of neuronal damage [60].  
Caspase 3 mediated apoptosis was also addressed. A significant reduction of caspase 3 
activity and diminution of Bax protein were found in MCR9 treated SAMP8 mice. 
Because Bax is described as a pro-apoptotic protein, its diminution indicates a possible 
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protective role for I2-IR ligands in neurons [61]. By contrast, reduced levels of Bcl-2, 
considered an anti-apoptotic protein, deserve further studies. Several authors have 
indicated that when Bax is reduced, Bcl-2 is less necessary for blocking Bax dimer to 
form the mitochondrial pore; in this situation cells reduce the Bcl-2 levels as a control 
mechanism [62]. 
An increase in p-AKT was induced by the I2-IR ligands, whereas a decrease in ERK½ 
activation was observed. p-AKT inactivated GSK3β, a key kinase involved in the process 
of Tau hiperphosphorylation, by phosphorylation in Ser9. To this point, MCR5 and 
MCR9 treated SAMP8 mice showed an increase of Ser9 phosphorylated GSK3β and 
reduced Tau hyperphosphorylation.  
ERK½ inhibition (that reduction of p42/p44) by MCR5 and MCR9 can contribute to the 
beneficial effect elicited by I2-IR on synaptic markers and Tau phosphorylation processes. 
ERK½ belongs to a subfamily of MAPKs and plays diverse roles in the CNS, such as 
neuronal survival or death, synaptic plasticity, and learning and memory through 
phosphorylation of regulatory enzymes and kinases [63, 64]. Although crucial for 
neuronal survival, there is some evidence that prolonged activation of the ERK pathway 
can induce a deleterious effect to the cell [65, 66]. Interestingly, long-lasting ERK 
activation in neurons has been demonstrated in neurodegenerative diseases such as AD 
[67, 68] and PD [69]. Here, the inhibition of this kinase participates in post-translational 
modifications in cytoskeletal proteins such as Tau, ameliorating the neuronal network 
functioning, as demonstrated with an increase in synaptic markers. 
The relationship among MAPKs, such as ERK½, [70] and PI3K, such as AKT, and 
imidazoline receptors is well defined [71, 72]. In this respect, it has been described that 
either ERK or AKT can be associated with the multifunctional Fas/FADD complex [73, 
74]. Apoptosis is an important contributor to neurodegeneration [75], and in this regard, 
the FADD protein has been suggested as a putative biomarker for pathological processes 
associated with the course of clinical dementia [76]. It has been reported that total FADD 
has a central role in promoting apoptosis [77, 78] and its phosphorylation at Ser191/194 
mediates non-apoptotic actions such as cell growth and differentiation [79]. In our 
previous work, we demonstrated that MCR5 modified FADD phosphorylation (i.e., it 
increased the p-FADD/FADD ratio) in a kainate-treated rat model [35]. These results 
could explain the modulation of proteins from the apoptotic pathway mentioned before 
(e.g., a diminution in caspase 3 activation and significant changes in Bcl-2 and Bax), 
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which seems to favor anti-apoptotic actions mediated through I2-receptors, and especially 
by MCR5. 
Tau hyperphosphorylation is a histological trend in many neurodegenerative diseases 
characterized by cognitive decline, including AD. Therefore we studied APP processing 
pathways. Aberrant APP processing is a hallmark of cognitive decline diseases [80]. To 
assess the capacity of the tested compounds to modify this pathological hallmark, we 
evaluated APP fragments, specifically, sAPPα and sAPPβ. Despite neither APP fragment 
reaching significance in either I2-IR ligand treated SAMP8 mice group, we found a clear 
tendency, which indicates the non-amyloidogenic pathway preference. Moreover, sAPPα 
is described as a neuroprotective, neurotrophic and cell excitable regulator with synaptic 
plasticity [81]. Adam10 [82] and NEP [83] gene expression were higher in MCR5 and 
MCR9 treated mice groups than in non-treated animals. In sum, I2-IR ligands foster a 
diminution in the amyloidogenic pathway and higher degradation of β-amyloid in the 
SAMP8 mice model. 
In conclusion, the effectiveness of the two new I2-IR ligands in an in vivo female model 
for cognitive decline was demonstrated in this study. SAMP8 model mice are gated to 
neurodegenerative processes, such as AD, and our research has shown that MCR5 and 
MCR9 can open new therapeutic avenues against these pathological conditions that 
currently have unmet medical needs. Although different authors have previously 
indicated the relationship between I2-IR and cognitive decline, this study is the first 
experimental evidence that demonstrates the possibility of using this receptor as a target 
for cognitive impairment. Here, we demonstrate that this strategy could represent a future 
approach to treating devastating conditions such as AD. 
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kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; FADD, Fas-associated 
protein with death domain; Gfap, glial fibrillary acidic protein; GSK3β, glycogen 
synthase kinase 3 beta; Hmox1, heme oxygenase (decycling) 1; I2-IR, I2-Imidazoline 
receptors; Il-1β, interleukin 1 beta; Il-6, interleukin 6; MAO, monoamine oxidases; 
MAPK, mitogen-activated protein kinase; NEP, neprilysin; NMDA, N-methyl-D-
aspartate; NORT, novel object recognition test; OFT, open field test; OS, oxidative stress; 
PCR, polymerase chain reaction; PD, Parkinson’s disease; Pe, permeability; PI3K, 
phosphatidylinositol-4,5-bisphosphate 3-kinase; PSD95, postsynaptic density protein 95; 
SAMP8, senescence accelerated mouse prone 8; SPBD, spectrin breakdown; SEM, 
standard error of the mean; SOD1, superoxide dismutase 1; SYN, synaptophysin; TBP, 
tata-binding protein; TN, time with new object; Tnf-α, tumor necrosis factor alpha; TO, 
time with old object; WB, western blot. 
 
 
Figure 1. Representative I2-IR ligands. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
Figure 2. Structure of I2-IR ligands MCR5 and MCR9.   
 
Figure 3. Acute and repeated measurement of the hypothermic effect of compound 
MCR9 in mice. (A) Effect of acute treatment with MCR9 (20 mg/kg, i.p.) on rectal body 
temperature in mice. Columns are means ± SEM of the difference (Δ, 1 h - basal value) 
in body temperature (°C) for MCR9-treated mice compared with vehicle-treated Control 
mice. Data were analyzed using Student’s t-test. **p<0.01. (B) Effect of repeated (5 days) 
treatments with MCR9 (20 mg/kg, i.p., closed circles) on rectal body temperature in mice. 
Circles are means ± SEM of the difference (Δ, 1 h - basal value) in body temperature (°C) 
for MCR9-treated mice compared with vehicle-treated Controls. Data were analyzed 
using repeated measures ANOVA followed by Sidak’s multiple comparison test. 
**p<0.01, ***p<0.001; (n=6-7 animals per group). 
 
Figure 4. Behavioral and cognitive improvement in 12-month-old treated SAMP8 mice 
with both I2-IR ligands. (A) A significant increase in the distance traveled in the open 
field test in the I2-IR ligand treated groups compared with the Control group. (B) A 
significant increase in the percentage of time in the center zone of the opened field test in 
the MCR5 treated group compared with the Control group, and no significant difference 
between the MCR9 and Control groups. (C) A significant increase in the number of total 
rears of the opened field test among groups. (D) The time spent in the opened arms of the 
EPM did not differ among groups. (E) A significant increase in the time spent in the 
closed arms among the Control group compared with the treated groups. (F) A significant 
increase in the number of total rears of the EPM in the MCR5 group compared with the 
Control group. (G) The results of the NORT in the short-term memory (2 h) revealed a 
significant increase in both I2-IR ligand treated groups compared with the Control group 
as well as a significant reduction in the DI of the MCR9 group compared with MCR5 
group, and (H) a significant increase in the DI of the long-term memory (24 h) in both I2-
IR ligand treated groups compared with the Control group. Data expressed as means ± 
SEM (n=8-10 animals per group) and analyzed using one-way ANOVA followed by 
Tukey’s post hoc test for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001.  
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Figure 5. Reduced OS and inflammatory markers in 12-month-old treated SAMP8 mice 
with both I2-IR ligands. (A) There was a significant reduction in the hydrogen peroxide 
concentration in both I2-IR ligand treated groups compared with the Control group in 
homogenates of the hippocampus tissue. (B) A significant reduction in SOD1 protein 
levels in the MCR5 group compared with the Control group and no difference between 
the MCR9 and Control groups. (C) A significant reduction in Gfap protein levels in the 
MCR5 and MCR9 groups compared with the Control group. (D) Gene expression of 
antioxidant enzymes in the mouse hippocampus. A significant increase in Hmox1 gene 
expression, but not for Aox1 and Cox2, among both I2-IR ligand treated groups and the 
Control group. (E) A significant reduction in gene expression of Il-1β and Tnf-α in the 
MCR5 group compared with the Control group, and a tendency for the same genes to 
reduce in the MCR9 group. However, Il-6 gene expression did not differ among groups. 
Values in bar graphs are adjusted to 100% for protein level of the Control group. Gene 
expression levels were determined by real-time PCR. Data are expressed as means ± SEM 
(n=4-5 animals per group) and analyzed using one-way ANOVA followed by Tukey’s 
post hoc test for multiple comparisons. *p<0.05. 
 
Figure 6. Changes in synaptic markers and apoptotic factors in 12-month-old treated 
SAMP8 mice with both I2-IR ligands. (A) A significant increase in PSD95 protein levels 
in the MCR5 group compared with the other two groups. (B) A tendency for SYN protein 
levels to increase in both I2-IR ligand treated groups compared with the Control group. 
(C) A tendency for a reduction in the spectrin fragment SPBD 150, and a significant 
reduction in the spectrin fragment SPBD 120 in the MCR9 group compared with the 
Control group. (D) A significant reduction in Caspase-3 protein levels in both I2-IR 
ligand groups compared with the Control group. (E) A significant reduction in Bcl-2 
protein levels in both I2-IR ligand groups compared with the Control group. (F) A 
significant reduction in Bax protein levels in the MCR9 group compared with the other 
groups. Values in bar graphs are adjusted to 100% for protein level of the Control group. 
Representative WB for each protein in the mouse hippocampus is shown. Data are 
expressed as means ± SEM (n=5 animals per group) and analyzed using one-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons. *p<0.05, 
**p<0.001. 
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Figure 7. Changes in kinase signaling pathways reduced hyperphosphorylation of Tau in 
12-month-old SAMP8 mice treated with both I2-IR ligands. (A) A significant increase in 
the p-AKT ratio in the MCR5 group compared with the other two groups. (B) A 
significant increase in inactive p-GSK3β (Ser9) protein levels in both I2-IR ligand treated 
groups compared with the Control group. (C) A significant reduction in p-ERK½ in both 
I2-IR ligand treated groups compared with the Control group. (D) Changes in the p-
CDK5/CDK5 ratio induced by MCR5 and MCR9 treatment. (E) Changes in the p25/p35 
ratio in the MCR5 and MCR9 groups compared with the Control group. Representative 
WB are shown. (F) A reduction in p-Tau (Ser396), as well as a significant reduction in p-
tau (Ser404) in both I2-IR ligand treated groups compared with the Control group. Values 
in bar graphs are adjusted to 100% for protein level of the Control group. Data are 
expressed as means ± SEM (n=5 animals per group) and analyzed using one-way 
ANOVA followed by Tukey’s post hoc test for multiple comparisons. *p<0.05, 
**p<0.01, ***p<0.001. 
 
Figure 8. Changes in APP processing and Aβ degradation enzymes in 12-month-old 
SAMP8 mice treated with both I2-IR ligands. Representative WB of the APP and its 
fragments. (A) A significant increase in sAPPα protein levels in the MCR9 group 
compared with the Control group, and no significant difference between the MCR5 and 
Control groups. (B) A significant reduction in sAPPβ protein levels in the MCR5 group 
compared with the Control group, and no significant difference between the MCR9 and 
Control groups. (C) A significant increase in Adam10 gene expression in the MCR5 
group compared with the Control group, and no significant difference in the MCR9 
group. (D) A significant increase in NEP gene expression in the MCR5 group compared 
with the Control group, and no significant difference in the MCR9 group. Values in bar 
graphs were adjusted to 100% for protein level of the Control group. Gene expression 
levels were determined by real-time PCR. Data are expressed as means ± SEM (n=4-5 
animals per group) and analyzed using one-way ANOVA followed by Tukey’s post hoc 
test for multiple comparisons. *p<0.05.  
 
Behavioral and cognitive improvement induced by novel imidazoline I2 receptor 
ligands in female SAMP8 mice 
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As populations increase their life expectancy, age-related neurodegenerative disorders 
such as Alzheimer’s disease (AD) have become more common. I2-Imidazoline receptors 
(I2-IR) are widely distributed in the central nervous system (CNS), and dysregulation of 
I2-IR in patients with neurodegenerative diseases have been reported, suggesting their 
implication in cognitive impairment. This evidence supports that potential high-affinity 
selective I2-IR ligands could contribute to the delay of the neurodegeneration. In vivo 
studies in the female Senescence Accelerated Mouse-Prone 8 mice (SAMP8) showed that 
treatments with our previously reported I2-IR ligands, MCR5 and MCR9, produce 
beneficial effects in behavior and cognition. Besides, changes in molecular pathways 
implicated in oxidative stress (OS), inflammation, synaptic plasticity, and apoptotic cell 
death were studied. Additionally, treatments with these I2-IR ligands diminished the 
amyloid precursor protein (APP) processing pathway and increased Aβ degrading 
enzymes in the hippocampus of SAMP8 mice. Thus, altogether these results demonstrate 
the neuroprotective role for these new I2-IR ligands through specific pathways, being 
promising therapeutic agents in brain disorders and age-related neurodegenerative 
diseases.  
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INTRODUCTION 
Imidazoline receptors (non-adrenergic receptors for imidazolines) [1] have been 
identified as one of the promising biological targets that deserve further investigation by 
using multidisciplinary  build comprehensive understanding of their pharmacological 
possibilities. To date, three main imidazoline receptors have been identified, namely I1, 
I2 and I3-IR, as binding sites that recognize different radiolabelled ligands involving 
different locations, and physiological functions [2-4]. The pharmacological 
characterization of I1-IR is understood the best yielding antihypertensive drugs 
moxonidine [5] or rilmenidine [6]. To date, I2-IR have not been structurally described 
although the group of García-Sevilla has defined distinct binding proteins corresponding 
to subgroups of I2-IR sites [7]. I2-IR are involved in analgesia [8] glial tumors [9], 
inflammation [10] and in a plethora of brain disorders [11, 12], including AD [13,14] and 
Parkinson’s disease (PD) [15], and different psychiatric disorders [16]. The efficacy of 
the analgesic CR4056 in osteoarthritis has advanced this compound in the first-in-class 
I2-IR ligand to achieve phase II clinical trials [17]. I2-IR are widely distributed in the 
CNS, binds imidazoline-based compounds [18, 19] as idazoxan or valldemossine [20], 
and have been associated with the catalytic site of monoamine oxidase enzyme (MAO) 
[21]. A neuroprotective role for I2-IR was described through the pharmacological 
activities observed for their ligands [22]. Idazoxan reduced neuron damage in the 
hippocampus after global ischemia in the rat brain [23] and agmatine, identified as the 
endogenous I2-IR ligand [24], has demonstrated modulatory actions in several 
neurotransmitters that produce neuroprotection both in vitro and in rodent models [25]. 
The compelling evidence has demonstrated that other selective I2-IR ligands (Figure 1) 
are neuroprotective against cerebral ischemia in vivo [26, 27], induce beneficial effects in 
several models of chronic opioid therapy, lead to neuroprotection by direct blocking of 
N-methyl-D-aspartate receptor (NMDA) mediated intracellular [Ca2+] influx [28], or 
provoke morphological/biochemical changes in astroglia that are neuroprotective after 
neonatal axotomy [22], amongst others.  
At a cellular level, I2-IR are situated in the outer membrane of mitochondria in astrocytes 
[29], and a direct physiological function of glial I2-imidazoline preferring sites in the 
regulation of the level of the astrocyte marker Glial fibrillary acidic protein (Gfap) has 
been proposed [30]. Besides, it is widely known that astrogliosis is a pathophysiological 
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trend in brain neurodegeneration as in AD [31]. The density of I2-IR is markedly increased 
in the brains of patients with AD [13], as increases in the brain after gliosis [32]. 
The pharmacological characterization of these receptors relies on the discovery of 
selective I2-IR ligands devoid of high affinity for I1-IR and α2-adrenoceptors. The 
reported I2-IR ligands are structurally restricted featuring rigid substituted pattern 
imidazolines, and most of them are not entirely selective and interact also with α-
adrenoceptors [19] and causing side effects [33]. Our chemistry program aimed to find 
new selective I2-IR ligands to increase the arsenal of pharmacological tools to exploit the 
therapeutic potential of I2-IR in neuroprotection.  
Thus, we have recently synthesized a series of new chemical scaffolds, 2-imidazolin-4-
yl)phosphonates [34], by an isocyanide-based multicomponent reaction under microwave 
irradiation avoiding the use of solvents. The experimental synthetic conditions fulfill the 
principles of green chemistry giving access to novel compounds with high selectivity and 
affinity for I2-IR. Among them, we tested MCR5 [diethyl (1-(3-chloro-4-fluorobenzyl)-
5,5-dimethyl-4-phenyl-4,5-dihydro-1H-imidazol-4-yl)phosphonate] in previous work to 
demonstrate neuroprotective and analgesic effects, showing promising results in models 
of brain damage [35]. In particular, mechanisms of neuroprotection related to regulation 
of apoptotic pathways or inhibition of p35 cleavage mediated by this new active 
compound have been found. In the present work, we explored the behavioral and 
cognitive status, including molecular changes associated with age and neurodegenerative 
processes presented by SAMP8 when treated with these new highly selective I2-IR 
ligands MCR5 and MCR9 [methyl 1-(3-chloro-4-fluorobenzyl)-5,5-dimethyl-4-phenyl-
4,5-dihydro-1H-imidazole-4-carboxylate] (Figure 2). SAMP8 is a naturally occurring 
mouse strain that displays a phenotype of accelerated aging with cognitive decline, as 
observed in AD, and widely used as a feasible rodent model of cognitive dysfunction 
[36]. To the best of our knowledge, this manuscript reports the first study including 
cognitive and behavioral parameters of novel I2-IR ligands in a well-characterized animal 
model for studying brain aging and neurodegeneration.  
 
 
Material and methods 
Synthesis of I2-IR ligands MCR5 and MCR9.  
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The compounds were prepared using our previously optimized conditions [34]. I2-IR pKi 
for MCR5 and MCR9 were determined as 9.42±0.16 nM and 8.85±0.21 nM respectively, 
showing both compounds also high selectivity vs. α2 adrenergic receptors (457 and 1862, 
respectively) [35].  
The Blood-Brain Barrier (BBB)- determination method 
The in vitro permeability (Pe) of the novel compounds through a lipid extract of the 
porcine brain was determined using a mixture of PBS/EtOH 70:30. The concentration of 
drugs was determined using a UV/VIS (250-500 nm) plate reader. Assay validation was 
carried out by comparison of the experimental and reported permeability values of 14 
commercial drugs (see supporting information), which provided a good linear correlation: 
Pe (exp) = 1.003 Pe (lit) _ 0.783 (R2 = 0.93). Using this equation and the limits established 
by Di et al. [37] for BBB permeation, the following ranges of permeability were 
established: Pe (10-6 cm·s-1)>5.18 for compounds with high BBB permeation (CNS+); Pe 
(10-6 cm·s-1)<2.06 for compounds with low BBB permeation (CNS_); and 5.18>Pe (10-6 
cm·s-1)>2.06 for compounds with uncertain BBB permeation (CNS±). 
Measurements of hypothermic effects  
For this study, a total of 25 adult male CD-1 mice (30-40 g) bred in the animal facility at 
the University of the Balearic Islands were used. Mice were housed in standard cages 
under defined environmental conditions (22°C, 70% humidity, and 12 h light/dark cycle, 
lights on at 8:00 AM) and with free access to a standard diet and tap water.  Experimental 
procedures followed the ARRIVE [38] and standard ethical guidelines (European 
Communities Council Directive 86/609/EEC and Guidelines for the Care and Use of 
Mammals in Neuroscience and Behavioral Research, National Research Council 2003) 
and were approved by the Local Bioethical Committee (UIB-CAIB). All efforts were 
made to minimize the number of mice used and their suffering. 
Mice were handled, weighted, and habituated to the experimenter for two days before any 
experimental procedures. For the acute treatment, mice received a single dose of MCR9 
(20mg/kg, i.p., n=6) or vehicle (a mixture of equal parts of DMSO and saline, i.p., n=7), 
while for the repeated treatment mice were daily treated with MCR9 (20mg/kg, i.p., n=6) 
or vehicle (a mixture of equal parts of DMSO and saline, i.p., n=6) for 5 consecutive days. 
The hypothermic effect of compound MCR9 was evaluated by measuring rectal 
temperature before any drug treatment (basal value) and 1h after drug injection by a rectal 
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probe connected to a digital thermometer (Compact LCD thermometer, SA880-1M, RS, 
Corby, UK). Mice were sacrificed right after the last measurement of rectal temperature. 
SAMP8 in vivo experiments 
SAMP8 female mice (n=26) (12-month-old) were used to carry out cognitive and 
molecular analyses. We divided these animals randomly into three groups: SAMP8 
Control (SP8-Ct, n=10) and SAMP8 treated with I2-IR ligands (MCR5, n=8) and 
(MCR9, n=8). Animals had free access to food and water and were kept under standard 
temperature conditions (22±2°C) and 12h: 12h light-dark cycles (300 lux/0 lux). MCR5 
and MCR9 (5mg/Kg/day) were dissolved in 1,8% 2-hydroxypropyl-β-cyclodextrin and 
administered through drinking water for 4 weeks. Water consumption was controlled each 
week, and I2-IR ligands concentrations were adjusted accordingly to reach the optimal 
dose. 
Studies and procedures involving mice brain dissection and subcellular fractionation were 
performed by the ARRIVE [38] and international guidelines for the care and use of 
laboratory animals (see above) and approved by the Ethical Committee for Animal 
Experimentation at the University of Barcelona. 
Open Field (OFT), Elevated Plus Maze (EPM), and Novel Object Recognition Test 
(NORT) 
The OFT apparatus was a white polywood box (50x50x25cm). The floor was divided into 
two areas defined as center zone and peripheral zone (15cm between the center zone and 
the wall). Behavior was scored with SMART® ver.3.0 software, and each trial were 
recorded for later analysis, utilizing a camera situated above the apparatus. 26 mice (n=8-
10 per group) were placed at the center and allowed to explore the box for 5 min. 
Afterward, mice were returned to their home cages, and the OFT apparatus was cleaned 
with 70% EtOH. The parameters scored included center staying duration, rears, 
defecations, and the distance traveled, calculated as the sum of total distance traveled in 
5 min.   
The EMP apparatus consists of opened arms and closed arms, crossed in the middle 
perpendicularly to each other, and a central platform (5×5cm) constructed of dark and 
white plywood (30×5×15cm). To initiate the test session, 26 mice (n=8-10 per group) 
were placed on the central platform, facing an open arm, and allowed to explore the 
apparatus for 5 min. After the 5 min test, mice were returned to their home cages, and the 
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EPM apparatus was cleaned with 70% EtOH and allowed to dry between tests. Behavior 
was scored with SMART® ver.3.0 software, and each trial was recorded for later analysis, 
utilizing a camera fixed to the ceiling at the height of 2.1m and situated above the 
apparatus. The parameters recorded included time spent on opened arms, time spent on 
closed arms, time spent in the center zone, rears, defecation and urination. 
The NORT protocol employed was a modification of those of Ennaceur and Delacour 
[39]. In brief, 26 mice (n=8-10 per group) were placed in a 90°, two-arm, 25-cm-long, 
20-cm-high, 5-cm-wide black maze. The walls could be removed for easy cleaning. Light 
intensity in mid-field was 30 lux.  Before performing the test, the mice were individually 
habituated to the apparatus for 10 min for 3 days. On day 4, the animals were submitted 
to a 10 min acquisition trial (first trial), during which they were placed in the maze in the 
presence of two identical, novel objects (A+A or B+B) at the end of each arm. A 10 min 
retention trial (second trial) was carried out 2h and 24h later, with one of the two objects 
changed. During these second trials, mice behavior was recorded with a camera. The 
Time New object (TN) and the Time Old object (TO) were measured. A Discrimination 
Index (DI) was defined as (TN−TO)/(TN+TO). The maze and the objects were cleaned 
with 96% EtOH after each test to eliminate olfactory cues. 
Brain processing 
Mice were euthanized by cervical dislocation one day after the behavioral and cognitive 
tests finished. Brains were immediately removed from the skull. The hippocampus was 
then isolated and frozen in powdered dry ice. They were maintained at -80°C for further 
use. Tissue samples were homogenized in lysis buffer containing phosphatase and 
protease inhibitors (Cocktail II, Sigma-Aldrich). Total protein levels were obtained and 
the method of Bradford determined protein concentration.   
 
Protein levels determination by Western blot (WB) 
For WB, aliquots of 15µg of hippocampal protein were used. Protein samples from 15 
mice (n=5 per group) were separated by SDS-PAGE (8-12%) and transferred onto PVDF 
membranes (Millipore). Afterward, membranes were blocked in 5% non-fat milk in 0,1% 
Tween20 TBS (TBS-T) for 1h at room temperature, followed by overnight incubation at 
4°C with the primary antibodies listed in Table 1 (Supporting information). Membranes 
were washed and incubated with secondary antibodies for 1hat room temperature. 
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Immunoreactive proteins were viewed with a chemiluminescence-based detection kit, 
following the manufacturer’s protocol (ECL Kit; Millipore) and digital images were 
acquired using a ChemiDoc XRS+ System (BioRad). Semi-quantitative analyses were 
carried out using ImageLab software (BioRad), and results were expressed in arbitrary 
units, considering control protein levels as 100%. Protein loading was routinely 
monitored by immunodetection of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). 
 
Determination of OS in the hippocampus 
Hydrogen peroxide (H2O2) from 12 mice (n=4 per group) was measured in hippocampal 
tissue protein extracts obtained as described above, as an indicator of OS and it was 
quantified using the hydrogen peroxide Assay Kit (Sigma-Aldrich, St. Louis, MI) 
according to the manufacturer’s instructions. 
RNA extraction and gene expression determination 
Total RNA isolation was carried out using TRIzol® reagent according to manufacturer’s 
instructions. The yield, purity, and quality of RNA were determined 
spectrophotometrically with a NanoDrop™ ND-1000 (Thermo Scientific) apparatus and 
an Agilent 2100B Bioanalyzer (Agilent Technologies). RNAs with 260/280 ratios and 
RIN higher than 1.9 and 7.5, respectively, were selected. Reverse Transcription-
Polymerase Chain Reaction (RT-PCR) was performed as follows: 2μg of mRNA was 
reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Real-time quantitative PCR (qPCR) was employed to quantify the mRNA 
expression of OS genes Heme oxygenase (decycling) 1 (Hmox1), Aldehyde oxidase 1 
(Aox1), Cyclooxygenase 2 (Cox2), inflammatory genes Interleukin 6 (Il-6), Interleukin 1 
beta (Il-1β), Tumor necrosis factor alpha (Tnf-α), Amyloid processing gene disintegrin 
and metalloproteinase domain-containing protein 10 (Adam10) and amyloid degradation 
gene Neprilysin (NEP). The primers were listed in Table 2 (Supporting information). 
SYBR® Green real-time PCR was performed in a Step One Plus Detection System 
(Applied-Biosystems) employing SYBR® Green PCR Master Mix (Applied-Biosystems). 
Each reaction mixture contained 7.5μL of cDNA(which concentration was 2μg), 0.75μL 
of each primer (which concentration was 100nM), and 7.5μL of SYBR® Green PCR 
Master Mix (2X).  
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TaqMan-based real-time PCR (Applied Biosystems) was also performed in a Step One 
Plus Detection System (Applied-Biosystems). Each 20μL of TaqMan reaction contained 
9μL of cDNA (25ng), 1μL 20X probe of TaqMan Gene Expression Assays and 10μL of 
2X TaqMan Universal PCR Master Mix.  
Data were analyzed utilizing the comparative Cycle threshold (Ct) method (ΔΔCt), where 
the housekeeping gene level was used to normalize differences in sample loading and 
preparation. Normalization of expression levels was performed with actin for SYBR® 
Green-based real-time PCR results and Tbp for TaqMan-based real-time PCR. Each 
sample (n=4-5 per group) was analyzed in duplicate, and the results represent the n-fold 
difference of the transcript levels among different groups. 
Data analysis 
The statistical analysis were conducted using GraphPad Prism ver. 6 statistical software. 
Data were expressed as the mean ± Standard Error of the Mean (SEM). Means were 
compared with One-way Analysis of variance (ANOVA) and Tukey’s post hoc test or 
two-tailed Student’s t-test when it was necessary. Statistical significance was considered 
when p values were <0.05. Statistical outliers were performed out with Grubbs' test and 
were removed from the analysis. 
RESULTS  
BBB permeation assay for I2-IR ligands MCR5 and MCR9 
The tested compounds MCR5 and MCR9 had Pe values of 13.5±0.9 and 26.9±1.7, 
respectively, well above the threshold for high BBB permeation, so that they were 
predicted to be able to cross the BBB and reach their biological target in CNS. 
Supplementary information on results analysis could be found in supporting material 
(Table 3). 
 
Hypothermic effects of compound MCR9 in mice 
It is known that selective I2-IR ligands induced hypothermia in rodents [4]. In particular, 
the hypothermic effect of compound MCR5 in mice was evaluated in a recent study from 
our research group (results for compound 2c in ref 35) [35]. Similar to MCR5, the 
compound MCR9 induced mild hypothermia as assessed by a moderate reduction (-
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2.3°C) in rectal temperature 1h after injection at the tested dose of 20mg/kg in adult CD-
1 mice and as compared with vehicle-treated controls (Figure 3A, day 1). While repeated 
(5 days) administration (20mg/kg) revealed persistent hypothermic effects of MCR9 
from days 1 to 4 (range from -2.3 to -3.2°C), on day 5 no significant effects were observed 
in body temperature (-1.8°C change) as compared to vehicle-treated controls (Figure 3B).  
Beneficial effects on behavior and cognition induced by MCR5 and MCR9 in 
SAMP8 
Results obtained in OFT demonstrated that both compounds were able to increase 
locomotor activity and time spent in the center zone (Figures 4A and B). Besides, a 
significant increment in the vertical activity, quantified by the number of total rears, was 
observed in mice treated with MCR5 or MCR9 in OFT and the EPM (Figures 4C and F). 
EPM data indicated a reduction in anxiety-like behavior by a significant decrease time 
spent in closed arms for a treated animal compared to control (Figure 4E). These results 
are supported by a preference for opened arms, although, not significant for MCR5 
(Figure 4D). Moreover, a significant increase in the DI indicates an improved 
performance in recognition of the new object in the NORT between MCR5- and MCR9-
treated SAMP8 compared to the SAMP8 control group. A robust effect in short (2h) and 
long-term (24h) memory was found for the two tested compounds (Figures 4G and H).  
OS and inflammatory markers reduced by MCR5 and MCR9 in SAMP8  
OS and neuroinflammation are thought to be key risk factors in the development of 
neurodegeneration. The hydrogen peroxide levels in the hippocampus were significantly 
reduced in brains of treated mice with either MCR5 or MCR9 in comparison with the 
control group (Figure 5A). Of note, superoxide dismutase 1 (SOD1) protein levels were 
reduced by MCR5 but not by MCR9 treated mice (Figure 5B). Moreover, Hmox1 gene 
expression, an important key enzyme in cellular antioxidant-defense, was also 
significantly increased with both candidates, MCR5 and MCR9 (Figure 5D). Other OS 
markers as Aox1 or Cox2 were not significantly altered (Figure 5D). Regarding the 
inflammation markers, no changes were observed in Il-6 gene expression for tested 
compounds, but a significant decrease in Il-1β and Tnf-α for MCR5 treated SAMP8 was 
found (Figure 5E). Moreover, a significant diminution in Gfap gene expression was 
determined, reinforcing the prevention of inflammatory processes by MCR5 and MCR9 
(Figure 5C). 
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Changes in synaptic markers and apoptotic factors induced by MCR5 and MCR9 
in SAMP8 
MCR5, but not MCR9, induced an increase in Postsynaptic density protein 95 (PSD95) 
protein levels (Figure 6A). Protein levels for Synaptophysin (SYN), a presynaptic protein, 
showed a slight increase for both compounds, although did not reach significance (Figure 
6B). To determine the implication of proteolytic processes in the MCR5 and MCR9 
compounds, we found reduced levels of calpain (data not shown) with a significant 
diminution in 150 α-spectrin breakdown fragment (SPBD) (Figure 6C). Besides, MCR9 
and MCR5 were able to reduce caspase-3 activity in SAMP8 hippocampi, because of the 
diminution of caspase-3 protein levels and 120 SPBD fragments that reached significance 
for MCR9 (Figure 6C and D). Moreover, B-cell lymphoma 2 (Bcl-2) levels were 
diminished, and Bcl-2-associated X (Bax), a key protein in the apoptotic cascade, was 
reduced by MCR5 (Figures 6E and F), supporting a possible implication of I2-IR in 
apoptosis processes.  
Changes in Mitogen-activated protein kinases (MAPK) signaling pathways reduced 
hyperphosphorylation of Tau induced by MCR5 and MCR9 in SAMP8 
Key proteins associated with molecular pathways disturbed in brain disorders and 
neurodegeneration were evaluated by WB. Interestingly, MCR5, but not MCR9, 
increased p-AKT/AKT ratio (protein kinase B) (Figure 7A). Accordingly, higher levels 
of inactivated Glycogen synthase kinase 3 beta (GSK3β), phosphorylated in Ser9, were 
determined (Figure 7B). Extracellular Signal-regulated Kinase (ERK½) inhibition by 
MCR5 and MCR9 was demonstrated by a reduction of p-ERK½ ratio, (Figure 7C). 
Furthermore, Cyclin-dependent kinases 5 (CDK5) measured by p-CDK5/CDK5 and 
p25/p35 ratio were also reduced (Figures 7D and E). Taking into account the results 
obtained on kinases CDK5, GSK3β, AKT, and ERK½, we studied Tau 
hyperphosphorylation levels in the hippocampus of SAMP8. A significant reduction in 
Tau phosphorylation in treated SAMP8 was found, specifically for Ser404 
phosphorylation site, whereas Ser396 phosphorylation site was reduced without reaching 
signification (Figure 7F).   
Changes in APP processing and Aβ degradation induced by MCR5 and MCR9 in 
SAMP8 
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We found a significant increase in sAPPα protein levels in MCR9 treated SAMP8 (Figure 
8A) and a significant reduction in sAPPβ protein levels in MCR5 (Figure 8B). Besides, 
a significant increase in gene expression for Adam10, an α-secretase that cleavage APP 
and NEP, an Aβ degrading enzyme (Figures 8C and D) in treated mice groups than in 
non-treated animals. 
DISCUSSION 
I2-IR have been related to several physiological and pathological processes, including 
CNS ones, such as pain [8], neuropathic pain [40], seizures [41, 42], and 
neurodegenerative diseases as AD [14, 43]. Our lab has a research line on the 
development of new high affinity and selectivity I2-IR ligands, maintaining imidazoline 
scaffold and incorporating several substituents in the imidazoline ring. Some of them 
were tested for the neuroprotective role previously [35].  
Given the enormous potential of I2-IR and their implications in brain disorders and 
neurodegenerative diseases such as AD, we set out to explore whether MCR5 and 
MCR9, two members of a structurally new family of I2-IR ligands, might improve the 
behavioral and cognitive status in the SAMP8 model. Main chemical structural 
differences were a phosphonate substituent on the imidazoline ring for MCR5 in contrast 
with an ester group for MCR9 (Figure 2).  
Published results from our lab demonstrated that MCR5 presented a pKi for the I2-IR of 
9.42±0.16 and high selectivity when compared with α2 receptors affinity [35]. Likewise, 
MCR9 is also a high-affinity I2-IR ligand (pKi 8.85±0.21) but with a higher selectivity 
against α2 receptors. Both MCR5 and MCR9 were predicted to be able to cross the BBB, 
a drug characteristic of importance when action is expected in the CNS. 
Previous studies have evaluated the effects of selective I2-IR ligands on inducing 
hypothermia in rodents [e.g., idazoxan or BU224] [44].  Accordingly, MCR5 can induce 
hypothermia in mice, and showed neuroprotective role in kainate-induced seizures, 
modifying levels of and Fas-associated protein with death domain (FADD) receptor [35]. 
While acute MCR5 (5 and 20mg/kg) induced mild hypothermia, repeated (20mg/kg, 5 
days) administration of MCR5 revealed significantly attenuated hypothermic effects 
from day 2 of treatment, which indicated the induction of tolerance to the hypothermic 
effects of the drug [35]. For MCR9 (20mg/kg) repeated (5 days) administration revealed 
persistent hypothermic effects up to day 4. These results suggest that the slow induction 
of tolerance to the hypothermic effects caused by MCR9 might be started following 5 
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days of drug administration, although a more extended treatment paradigm might be 
needed for confirmation. 
The hypothermic effects exerted by MCR5 and MCR9 might be relevant to induce 
neuroprotection, as it was previously proposed for some of the neuroprotective effects 
induced by the I2-IR selective ligand idazoxan. Several experiments have ascertained a 
possible role for hypothermia in mediating neuroprotection. For example, small drops in 
temperature exerted neuroprotection in cerebral ischemia [45] and are typically used in 
the clinic to improve the neurological outcome under various pathological conditions 
(e.g., stroke, brain injury). Although the mechanisms explaining the neuroprotective 
effects mediated by hypothermia are not well understood, some researchers suggested 
that they might be related to the inhibition of glutamate release [46]. 
SAMP8 has been studied as a non-transgenic murine mouse model of accelerated 
senescence and late-onset AD. These mice exhibit cognitive and emotional disturbances, 
probably due to the early development of pathological brain hallmarks, such as OS, 
inflammation, and activation of neuronal death pathways, which mainly affect cerebral 
cortex and the hippocampus [47, 48]. To date, this rodent model has not been used to test 
I2-IR ligands. Thus, this work is the first investigation about the effects of the 
improvement of cognitive impairment and behavior in this mice model after treatment 
with I2-IR ligands.  
Behavioral and cognitive effects were investigated through three well-established tests in 
SAMP8 the OFT, which is an experiment used to assay general locomotor activity and 
anxiety in rodents [49]; the EPM, one of the most widely used test for measuring anxiety-
like behavior [50] and the NORT, as a standard measure of cognition (short- and long-
term memory) [51].   
The OFT and EPM parameters indicated a reduction in the cognitive impairment through 
showing improved locomotor activity jointly with an anti-anxiousness effect. Likewise, 
the NORT results demonstrated an improvement in cognitive and short and long learning 
capabilities in hippocampal memory processes. Therefore, all the assessed parameters 
showed robust beneficial effects on cognition and behavior after MCR5 and MCR9 
treatment in SAMP8. 
Results in cognitive and behavioral effects were supported by a cellular and biochemical 
assessment of characteristic parameters related to cognitive decline and AD. The 
compelling evidence demonstrated a neuroprotective role for I2-IR. The neuroprotective 
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role can be related to OS and inflammation [52], by measuring OS indicators and 
inflammation markers in SAMP8 brain tissue treated with the I2-IR ligands, MCR5 and 
MCR9. Results showed significant reduced hydrogen peroxide levels in hippocampal 
tissue and increased Hmox1 gene expression in treated MCR5 and MCR9 SAMP8, but 
not in other sensors for OS as Aox1 or Cox2. SOD1 protein levels were reduced by MCR5 
but not by MCR9. Regarding inflammation markers, no changes were observed in Il-6 
gene expression for tested compounds, but a significant decrease in Il-1β and Tnf-α for 
MCR5 treated SAMP8 was found. In addition, reduced astrogliosis was found in treated 
animals, corroborating a reduced inflammatory environment in hippocampi of MCR5 
and MCR9 treated SAMP8. Altogether these results showed a relatively weak influence 
in OS and inflammation mechanisms by I2-IR ligands in SAMP8 [53-57]. However, a 
role for those two pathological conditions related to I2-IR ligands interaction cannot be 
discarded at all because MCR5 was able to elicit beneficial effects despite the old age of 
SAMP8. It is known that aged SAMP8 presented lower inflammation and OS due to being 
at the endpoint of the senescence process [56, 57]. Therefore it can be challenging to 
determine drug effects on these processes in aged SAMP8.  
MCR5 and MCR9 effects on key molecular markers for synapsis and apoptosis were 
studied to unravel the cognitive decline prevention by I2-IR ligands in SAMP8, which is 
characterized by alterations in those processes. In consonance with better cognitive 
performance, the compounds tested increased synaptic markers as SYN and PSD95, 
indicating a neuroprotective role for MCR5 and MCR9.  
There are several cellular and molecular pathways related to a better synaptic 
performance, including proteolytic and phosphorylation activities or apoptotic processes. 
Regarding proteolytic processes, calpain is an intracellular protease which cleaves the 
CDK5 activator p35 to a p25 fragment. MCR5 and MCR9 diminished calpain levels and 
activity with a reduced 150 SPBD fragment. Moreover, a significant p25 protein levels 
diminution was found in treated SAMP8. A decrease in p25 can also influence CDK5 
activity, implicated in Tau phosphorylation [58, 59]. These results indicate that CDK5 
phosphorylation activity should be diminished after I2-IR ligands treatment, corroborating 
results obtained previously for MCR5 in a kainate model of neuronal damage [60].  
Caspase 3 mediated apoptosis was also addressed. Significant reduction of caspase 3 
activity and diminution Bax protein were found in MCR9 treated SAMP8. Because Bax 
is described as a pro-apoptotic protein, its diminution indicates a possible protective role 
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for I2-IR ligands in neurons [61]. By contrast, reduced levels of Bcl-2, considered as an 
anti-apoptotic protein, deserve further studies; several authors indicate that when Bax is 
reduced, Bcl-2 is less necessary to block Bax dimer formation to form the mitochondrial 
pore, activating intrinsic apoptotic pathway, and as consequence cells reduce the Bcl-2 
levels as a control mechanism [62]. 
On the other hand, an increase in p-AKT was induced by the I2-IR ligands, whereas a 
decrease in ERK½ activation was observed. p-AKT is able to inactivate by 
phosphorylation in Ser9, GSK3β a key kinase in the process of Tau hyperphosphorylation 
and then in the neurofibrillary tangles formation together with CDK5. To this point, 
MCR5 and MCR9 treated SAMP8 showed an increase of Ser9 phosphorylated GSK3β 
and reduced Tau hyperphosphorylation.  
Regarding ERK½ inhibition (reduction of p42/p44) by MCR5 and MCR9, this effect can 
contribute to beneficial effect elicited by I2-IR on synaptic markers and Tau 
phosphorylation processes. ERK½ belongs to a subfamily of MAPKs and plays diverse 
roles in the CNS as neuronal survival or death, synaptic plasticity, and learning and 
memory through phosphorylation of regulatory enzymes and kinases, among others [63, 
64]. Although crucial for neuronal survival, there is some evidence that prolonged 
activation of the ERK pathway can induce a deleterious effect to the cell [65, 66].  
Interestingly, long-lasting ERK activation in neurons has been demonstrated in 
neurodegenerative diseases such as AD [67, 68] and PD [69]. Here, the inhibition of this 
kinase can participate in post-translational modifications in cytoskeletal proteins such as 
Tau, ameliorating the neuronal network functioning, as demonstrated with a synaptic 
markers increase. 
The relationship among MAPKs, such as ERK½, [70] and PI3K, as AKT, and imidazoline 
receptors is well defined [71, 72]. In this respect, it has been described that either ERK or 
AKT can be associated with the multifunctional Fas/FADD complex [73, 74]. It is known 
that apoptosis is an important contributor to neurodegeneration [75], and in this regard, 
FADD protein has been suggested as a putative biomarker for pathological processes 
associated with the course of clinical dementia [76]. It was described that total FADD has 
a central role in promoting apoptosis [77, 78] and its phosphorylation at Ser191/194 
mediates non-apoptotic actions such as cell growth and differentiation [79]. In previous 
work, we demonstrated that MCR5 was able to modify FADD phosphorylation (i.e., 
increased p-FADD/FADD ratio) in a kainate-treated rat model [35]. These results could 
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explain the modulation of proteins from the apoptotic pathway mentioned before (e.g., a 
diminution in caspase 3 activation and significant changes in Bcl-2 and Bax), which 
seems to favor anti-apoptotic actions mediated through I2-receptors, and especially by 
MCR5. 
Tau hyperphosphorylation is one of the histological trends in many neurodegenerative 
diseases characterized by cognitive decline, including ADtherefore we studied APP 
processing pathways. Aberrant APP processing is a hallmark of cognitive decline diseases 
[80]. To assess the capacity of the tested compounds to modify this pathological hallmark, 
we evaluated APP fragments, concretely sAPPα and sAPPβ. Despite both APP fragments 
did not reach signification for both I2-IR ligands treated groups, we found a clear 
tendency, which indicates the non-amyloidogenic pathway preference. Moreover, sAPPα 
is described as neuroprotective, neurotrophic and cell excitability and synaptic plasticity 
regulator [81], Adam10 [82] and NEP [83] gene expression were higher in MCR5, and 
MCR9 treated mice groups than in non-treated animals. In sum, I2-IR ligands foster a 
diminution in the amyloidogenic pathway and higher degradation of β-amyloid in 
SAMP8 mice model. 
In conclusion, the effectiveness of the two new I2-IR ligands in an in vivo female model 
for cognitive decline, gated to neurodegenerative processes, and AD, as is SAMP8, can 
open new therapeutic avenues against these pathological conditions with unmet medical 
needs. Although different authors have previously indicated the relationship between I2-
IR and cognitive decline, this study is the first experimental evidence that demonstrates 
the possibility to use this receptor as a target for cognitive impairment. Here, we 
demonstrate that this strategy could be a new challenge in the treatment of these 
devastating conditions in the future. 
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Figure 1. Representative I2-IR ligands. 
 
Figure 2. Structure of I2-IR ligands MCR5 and MCR9.   
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Figure 3. Acute and repeated measurement of the hypothermic effect of compound 
MCR9 in mice. (A) Effect of acute treatment with MCR9 (20mg/kg, i.p.) on rectal body 
temperature in mice. Columns are means ± SEM of the difference (Δ, 1h - basal value) in 
body temperature (°C) for MCR9-treated mice compared to vehicle-treated Control 
mice. Data were analyzed using Student t-test. **p<0.01. (B) Effect of repeated (5 days) 
treatments with MCR9 (20mg/kg, i.p., closed circles) on rectal body temperature in mice. 
Circles are means ± SEM of the difference (Δ, 1h - basal value) in body temperature (°C) 
for MCR9-treated mice compared to vehicle-treated Controls. Data were analyzed by 
using repeated measures ANOVA followed by Sidak’s multiple comparison test. 
**p<0.01, ***p<0.001; (n=6-7 animals per group). 
 
Figure 4. Behavioral and cognitive improvement in SAMP8 12-month-old treated mice 
with both I2-IR ligands. (A) A significant increase in the distance travelled in the open 
field test in I2-IR ligands treated groups in comparison with the Control group. (B) A 
significant increase in the percentage of time in the center zone of the opened field test in 
MCR5 treated group compared to the Control group, and no significant difference 
between MCR9 and the Control group. (C) A significant increase in the number of total 
rears of the opened field test among groups. (D) The time spent in the opened arms of the 
EPM did not differ among groups. (E) A significant increase in the time spent in the 
closed arms among Control group in comparison with treated groups. (F) A significant 
increase in the number of total rears of the EPM in MCR5 group in comparison with 
Control group. (G) The results of the NORT in the short-term memory 2h revealed a 
significant increase in both I2-IR ligands treated groups in comparison with the Control 
group as well as a significant reduction in the DI of MCR9 group compared to MCR5 
group, and (H) a significant increase in the DI of the long-term memory 24h in both I2-
IR ligands treated groups compared to the Control group. Data expressed as means ± 
SEM (n=8-10 animals per group) and analyzed using a One-way ANOVA followed by 
Tukey’s post hoc test for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001.  
Figure 5. Reduced OS and inflammatory markers in SAMP8 12-month-old treated mice 
with both I2-IR ligands. (A) There was a significant reduction in hydrogen peroxide 
concentration in both I2-IR ligands treated groups in comparison with the Control group 
in homogenates of the hippocampus tissue. (B) A significant reduction in protein levels 
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of SOD1 in MCR5 group compared to the Control group and no difference between 
MCR9 and Control group. (C) A significant reduction in protein levels of Gfap in MCR5 
and MCR9 in comparison with the Control group. (D) Gene expression of antioxidant 
enzymes in the mice hippocampus. A significant increase in Hmox1 gene expression, but 
not for Aox1 and Cox2, among both I2-IR ligands and Control group. (E) Significant 
reduction in gene expression of Il-1β and Tnf-α in MCR5 group in comparison with the 
Control group, and a tendency to reduce in MCR9 group for the same genes. However, 
Il-6 gene expression did not differ among groups. Values in bar graphs are adjusted to 
100% for protein level of the Control group. Gene expression levels were determined by 
real-time PCR. Data expressed as means ± SEM (n=4-5 animals per group) and analyzed 
using a One-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. 
*p<0.05. 
 
Figure 6. Changes in synaptic markers and apoptotic factors in 12-month-old treated 
SAMP8 mice with both I2-IR ligands. (A) A significant increase in protein levels of 
PSD95 in MCR5 group in comparison with the other two groups. (B) A tendency to 
increase in protein levels of SYN in both I2-IR ligands treated groups in comparison with 
the Control group. (C) There was a tendency to reduce in the spectrin fragment SPBD 
150, and a significant reduction in the spectrin fragment SPBD 120 in MCR9 group in 
comparison with the Control group. (D) A significant reduction in Caspase-3 protein 
levels in both I2-IR ligands group in comparison with the Control group. (E) A significant 
reduction in Bcl-2 protein levels in both I2-IR ligands group in comparison with the 
Control group. (F) A significant reduction in Bax protein levels among the MCR9 group 
and the other groups. Values in bar graphs are adjusted to 100% for protein level of the 
Control group. Representative WB for each protein in the hippocampus mice was 
showed. Data expressed as means ± SEM (n=5 animals per group) and analyzed using a 
One-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. *p<0.05, 
**p<0.001. 
 
Figure 7. Changes in kinases signaling pathways reduced hyperphosphorylation of Tau 
in 12-month-old SAMP8 treated with both I2-IR ligands. (A) Significant increase in the 
p-AKT ratio in the MCR5 group in comparison with the others two groups. (B) 
Significant increase of inactive p-GSK3β (Ser9) protein levels in both I2-IR ligands 
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treated groups compared to the Control group. (C) Significant reduction in p-ERK½ in 
both I2-IR ligands treated groups in comparison with the Control group. (D) Changes in 
p-CDK5/CDK5 ratio induced by MCR5 and MCR9 treatment. (E) Changes in p25/p35 
ratio in the MCR5 and MCR9 group in comparison with the Control group.  
Representative WB were showed. (F) A reduction in p-Tau (Ser396), as well as a 
significant reduction in p-tau (Ser404) in both I2-IR ligands treated groups in comparison 
with the Control group. Values in bar graphs were adjusted to 100% for protein level of 
the Control group. Data expressed as means ± SEM (n=5 animals per group) and 
analyzed using a One-way ANOVA followed by Tukey’s post hoc test for multiple 
comparisons. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 8. Changes in APP processing and Aβ degradation enzymes in SAMP8 12-month-
old treated with both I2-IR ligands. Representative WB of the APP, and its fragments. (A) 
Significant increase in sAPPα protein levels in MCR9 group compared to the Control 
group, and no significant difference between MCR5 and the Control group. (B) 
Significant reduction in sAPPβ in protein levels in MCR5 group compared to the Control 
group, and no significant difference between MCR9 and the Control group. (C) 
Significant increase in gene expression of Adam10 in MCR5 group compared to the 
Control group, and no significant difference in MCR9 group. (D) There was a significant 
increase in gene expression of NEP in MCR5 group compared to the Control group, and 
no significant difference in MCR9 group. Values in bar graphs were adjusted to 100% 
for protein level of the Control group. Gene expression levels were determined by real-
time PCR. Data expressed as means ± SEM (n=4-5 animals per group) and analysed using 
a One-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. 
*p<0.05.  
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